Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are effective for the treatment of non‐small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR), but responses are not durable as tumors develop resistance. DS‐1205c is a novel, specific, orally bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Koichi, Shiraishi, Yoshimasa, Murakami, Haruyasu, Horinouchi, Hidehito, Toyozawa, Ryo, Takeda, Masayuki, Uno, Makiko, Crawford, Nigel, McGill, Joseph, Jimbo, Takeshi, Ishigami, Masato, Takayama, Gensuke, Nakayama, Shintaro, Ohwada, Shoichi, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067098/
https://www.ncbi.nlm.nih.gov/pubmed/36621830
http://dx.doi.org/10.1002/cam4.5508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067098/
https://www.ncbi.nlm.nih.gov/pubmed/36621830
http://dx.doi.org/10.1002/cam4.5508

Ejemplares similares